Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30279427 | 0.95 | EGFR (0.77) | EGFR | |
| SCHEMBL23759587 | 0.95 | EGFR (0.77) | EGFR | |
| SCHEMBL23759615 | 0.94 | EGFR (0.69) | EGFR | |
| SCHEMBL23759711 | 0.93 | EGFR (0.68) | EGFR | |
| SCHEMBL23759574 | 0.92 | EGFR (0.69) | EGFR | |
| SCHEMBL23759653 | 0.91 | EGFR (0.56) | EGFR | |
| SCHEMBL23759625 | 0.90 | EGFR (0.56) | EGFR | |
| SCHEMBL23759584 | 0.89 | EGFR (0.69) | EGFR | |
| SCHEMBL23759824 | 0.89 | EGFR (0.59) | EGFR | |
| SCHEMBL23759624 | 0.88 | EGFR (0.66) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114885607-A | Quinolylphosphine oxygen compounds, compositions and uses thereof | 贝达药业股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-114885607-B | Quinolinylphosphine oxide compounds, compositions and uses thereof | 贝达药业股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| CN-114885607-A | Quinolylphosphine oxygen compounds, compositions and uses thereof | 贝达药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2021160087-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | EGFR, ABL1, ERBB2 | EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.